Skip to main content

Table 1 Patient characteristics

From: Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study

Characteristic

Mt + (n= 121)

Mt – (n= 163)

All (n= 284)

 

No.

%

No.

%

No.

%

Age, years

      

 Median (range)

66 (32–87)

 

65 (23–83)

 

65 (23–87)

 

 < 70

97

80

134

82

231

81

 ≥ 70

      
 

24

20

29

18

53

19

Gender

      

 Male

43

36

125

77

168

59

 Female

78

64

38

23

116

41

ECOG PS

      

 0-1

103

85

135

83

238

84

 > 2

18

15

28

17

46

16

Smoking status

      

 Yes

50

41

124

76

174

61

 No

71

59

39

24

110

39

Stage

      

 IIIB

6

5

19

12

25

9

 IV

115

95

144

88

259

91

EGFR mutation

      

 Exon 19 deletion

59

49

  

59

21

 Exon 21 L858R

57

47

  

57

20

 Exon 18 G719X

5

4

  

5

2

 Wild type

  

163

100

163

57

PCV

      

 Median (range)

1.6 (0.1-110.0)

 

2.3 (0.1-80.0)

 

2.0 (0.1-110.0)

 

 < 2.2 ng/ml

72

60

78

48

150

53

 ≥ 2.2 ng/ml

49

40

85

52

134

47

CEA

      

 Median (range)

8 (0.7-11942)

 

7 (0.5-14985)

 

7.4 (0.5-14985)

 

 < 5.0 ng/ml

45

37

63

39

108

38

 ≥ 5.0 ng/ml

76

63

100

61

176

62

  1. EGFR: epidermal growth factor receptor, Mt+: mutant EGFR, Mt-: wild-type EGFR, PCV: pretreatment CYFRA 21–1 value.